Interestingly, the main safety concern was not an increased risk of infection itself, but a delay to initiation of treatment due to IL-1 inhibition masking clinically important signs of infection (i.e. fever, swelling or redness), thus resulting in fatal infection [6, 91]. The gene discussed is IL1B; the disease is infection.